Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Beta Carotene
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avivagen Accelerates Plans for Commercial Launch of Its OxC-Beta™ Technology
Details : OxC-beta has been shown to have a multi-fold increase in the expression of the IFNGR1/CD119, TLR2, TLR4, CD14, and LY96/MD2 genes involved in pathogen defence.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2020
Lead Product(s) : Beta Carotene
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?